Developer docs
API playgroundTry for free, no card

Search company profiles

Chimera Research Group

Full company profile

uuid002e899

Namestring
Chimera Research Group
Legal namestring
Chimera Research Group, Inc.
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Chimera Research Group, Inc. is a privately held, subscription-based equity research firm founded in 2011 and operating under the laws of New Jersey, with its website indicating a San Francisco base. The company provides independent investment and trading ideas for the biotech and pharmaceutical sectors, covering both early-stage companies with impending FDA decisions or clinical trial results and mid-to-large-cap bio-pharma names with specific catalysts. Its product portfolio spans Research Reports, Trade Reports, Daily Updates, Charts and Technical Analysis, a Members-only Forum, and real-time alerts distributed via Twitter and email; premium add-ons include Direct Email access, disclosure of the team's own trades, and multi-year Biotech M&A Deal Databases (2018-2025). All research is conducted without compensation from covered companies, with personal holdings disclosed to subscribers.

The firm employs a small, multidisciplinary team — Research Analysts Jason Chew (former oncology drug discovery researcher at Telik and Exelixis) and David Sobek (PhD, contributing columnist for TheStreet.Com and Seeking Alpha), and Biotech Trading Analyst Joe Gantoss (28 years of technical analysis experience) — collectively bringing over 50 years of combined biotech and pharma expertise. Chimera's go-to-market is a content-led, self-serve subscription model priced at $99/month, $249/quarter, and $850/year (with a 7-day free trial on annual plans), supported by a freemium blog funnel, earned media coverage in outlets such as Yahoo Finance, NASDAQ, and FierceBiotech, and owned social channels on Twitter, StockTwits, and LinkedIn. The customer base spans institutional investors (hedge funds, venture capitalists), pharma industry professionals (executives, physicians, scientists), and retail/self-directed investors, with no enterprise-anchor or large-contract revenue concentration evident from the available data.

Short descriptiontext

Chimera Research Group is a privately held, subscription-based independent equity research service founded in 2011 that delivers biotech and pharmaceutical investment ideas, trade reports, technical analysis, and real-time alerts to institutional, professional, and retail investors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGenoa, Italy
HQ citystring
Genoa
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
biotech equity research, pharmaceutical investment analysis, clinical trial research, biotech trading reports, technical analysis charts
Industry2 codes
PRIMARYFSACAGAA
Equity Research
Financial & Insurance/Capital Markets & Securities/Securities Research & Analytics
SECONDARYBPAHALAE
Industry & Sector Research (Syndicated/Custom)
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Biotech Equity Research
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Subscription Services
TypeSubscription Recurring
Description

The primary revenue stream is subscription-based access to premium research content including daily updates, trade reports, research reports, charts and technical analysis, and access to a members-only forum. Subscribers pay recurring fees at monthly, quarterly, or annual intervals.

chimeraresearchgroup.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
Pricing details3 tiers
1Monthly subscription at $99/month
ModelSubscriptionBilling cadenceMonthly
Notes

Full access to all premium content including daily updates, research reports, trade reports, charts & technical analysis, members forum, real-time Twitter feed, team trades, and all previous reports.

chimeraresearchgroup.com
2Quarterly subscription at $249/quarter
ModelSubscriptionBilling cadencePay-as-you-go
Notes

All monthly features plus direct email access to analysts for more personalized inquiries.

chimeraresearchgroup.com
3Annual subscription at $850/year
ModelSubscriptionBilling cadenceAnnual
Notes

All features including direct email access, plus 7-day free trial period for new subscribers.

chimeraresearchgroup.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Chimera Research Group delivers a subscription-based equity research service for the biotech and pharmaceutical sectors, providing independent, actionable investment and trading ideas backed by comprehensive fundamental research. Coverage focuses on early-stage companies with impending FDA decisions or clinical trial results and on mid-to-large-cap bio-pharma companies with specific catalysts. Subscribers receive access to Research Reports, Trade Reports, Daily Updates, Charts & Technical Analysis, Real-Time Twitter/email alerts, and a Members-Only Forum that includes contributions from major biotech hedge fund managers and pharmaceutical executives.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Chimera Research Group is a subscription-based equity research service for the biotech and pharmaceutical sectors, providing independent investment and trading intelligence. The company offers a unified platform of six integrated service modules: Research Reports covering clinical trials and competitive analysis, Trade Reports with risk-reward optimization, Daily Updates on sector news, Charts & Technical Analysis with entry/exit points, a Members-only Forum with contributions from hedge fund managers and pharma executives, and Real-Time Updates via Twitter and email alerts. Premium features include access to the team's own trade positions and direct analyst communication. The company was founded in 2011 and focuses on early-stage companies with FDA decisions or clinical trial catalysts.

Product and service7 records
1Research Reports
CategoryEquity Research Reports
Description

Peer-reviewed fundamental research reports covering clinical trials, pipelines, and competitive landscapes of biotech and pharmaceutical companies, produced for subscribing investors and industry professionals.

2Trade Reports
CategoryTrade Reports
Description

Investment and trade analyses providing risk-reward profiles and entry/exit strategies using statistical, scientific, fundamental, and technical analysis, targeted at active biotech stock traders.

3Daily Update
CategoryDaily Sector Updates
Description

Daily news and development coverage of the biotech and pharmaceutical sectors delivered to subscribers as part of the Chimera Research Group subscription.

4Charts and Technical Analysis
CategoryTechnical Analysis
Description

Technical analysis reports with step-by-step chart walkthroughs that mark technical entry and exit points and key support lines for biotech and pharmaceutical stocks.

5Members-Only Forum
CategoryCommunity Forum
Description

Private online community where subscribers interact with Chimera Research Group founders, analysts, and guest contributors, including hedge fund managers from major biotech hedge funds and pharmaceutical executives.

6Real-Time Updates Service
CategoryReal-Time Alerts
Description

Real-time Twitter feed and email alert service providing instant communication of breaking news and biotech/pharma developments to subscribers.

7Biotech M&A Deal Database
CategoryReference Databases
Description

Standalone premium database tools tracking biotech mergers and acquisitions deals across multiple years (2018-2025), accessible to Chimera Research Group subscribers.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Online research and analytics platform providing stock ratings and trade ideas to retail investors — adjacent in delivering actionable trade recommendations at consumer price points.

2TheStreet
TypeBroad incumbent
Description

Financial news and commentary site where David Sobek writes a weekly biotech column — overlap in financial commentary audience and biotech coverage angle.

TypeDirect peer
Description

Subscription-based investment research platform with paid tiers, daily notes, and proprietary analyst views — comparable subscription research/business model to Chimera.

TypeEmerging player
Description

Analyst-rating aggregation and transparency platform serving retail investors; partially overlapping with Chimera's transparency-focused value prop (Team Trades disclosures).

TypeBroad incumbent
Description

Largest crowdsourced investment research publishing platform where Chimera's own analysts (Jason Chew, David Sobek, Joe Gantoss) contribute — overlapping content and audience, but free/contributor-led rather than subscription-led.

TypeDirect peer
Description

Independent equity research provider delivering fundamental analysis and reports to institutional and individual investors — a direct comparable in research-as-a-service.

TypeBroad incumbent
Description

Broad investment research and data powerhouse serving institutional and retail investors with analyst reports and ratings — overlapping investment-advice category but much wider mandate.

TypeDirect peer
Description

Subscription investment advisory publisher with sector-focused newsletters and paid tiers — comparable independent retail-investor research subscription model.

TypeDirect peer
Description

Subscription-based equity research firm offering stock analysis, rankings, and premium tiers — directly comparable to Chimera's paid research/reports subscription model.

TypeDirect peer
Description

Subscription investment research service with tiered memberships and stock recommendations, similar in pricing structure and retail-investor GTM to Chimera.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Chimera Research Group

Biotech Equity Researchchimeraresearchgroup.com

Chimera Research Group is a privately held, subscription-based independent equity research service founded in 2011 that delivers biotech and pharmaceutical investment ideas, trade reports, technical analysis, and real-time alerts to institutional, professional, and retail investors.

What Chimera Research Group does

Chimera Research Group, Inc. is a privately held, subscription-based equity research firm founded in 2011 and operating under the laws of New Jersey, with its website indicating a San Francisco base. The company provides independent investment and trading ideas for the biotech and pharmaceutical sectors, covering both early-stage companies with impending FDA decisions or clinical trial results and mid-to-large-cap bio-pharma names with specific catalysts. Its product portfolio spans Research Reports, Trade Reports, Daily Updates, Charts and Technical Analysis, a Members-only Forum, and real-time alerts distributed via Twitter and email; premium add-ons include Direct Email access, disclosure of the team's own trades, and multi-year Biotech M&A Deal Databases (2018-2025). All research is conducted without compensation from covered companies, with personal holdings disclosed to subscribers.

The firm employs a small, multidisciplinary team — Research Analysts Jason Chew (former oncology drug discovery researcher at Telik and Exelixis) and David Sobek (PhD, contributing columnist for TheStreet.Com and Seeking Alpha), and Biotech Trading Analyst Joe Gantoss (28 years of technical analysis experience) — collectively bringing over 50 years of combined biotech and pharma expertise. Chimera's go-to-market is a content-led, self-serve subscription model priced at $99/month, $249/quarter, and $850/year (with a 7-day free trial on annual plans), supported by a freemium blog funnel, earned media coverage in outlets such as Yahoo Finance, NASDAQ, and FierceBiotech, and owned social channels on Twitter, StockTwits, and LinkedIn. The customer base spans institutional investors (hedge funds, venture capitalists), pharma industry professionals (executives, physicians, scientists), and retail/self-directed investors, with no enterprise-anchor or large-contract revenue concentration evident from the available data.

Chimera Research Group firmographics

Firmographics
Name
Chimera Research Group
Legal name
Chimera Research Group, Inc.
Website
https://chimeraresearchgroup.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
Chimera Research Group is a privately held, subscription-based independent equity research service founded in 2011 that delivers biotech and pharmaceutical investment ideas, trade reports, technical analysis, and real-time alerts to institutional, professional, and retail investors.
Ownership category
akta.pro rank

Chimera Research Group industry classification

Industry
Product category
Biotech Equity Research
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSACAGAA
Equity Research
Financial & Insurance/Capital Markets & Securities/Securities Research & Analytics
SECONDARYBPAHALAE
Industry & Sector Research (Syndicated/Custom)

Keywords

  • Biotech equity research
  • Pharmaceutical investment analysis
  • Clinical trial research
  • Biotech trading reports
  • Technical analysis charts

Where Chimera Research Group is headquartered

Location

Headquarters

HQ city
Genoa
HQ country
Italy
HQ region
Europe

Markets served

Chimera Research Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Subscription Services: The primary revenue stream is subscription-based access to premium research content including daily updates, trade reports, research reports, charts and technical analysis, and access to a members-only forum. Subscribers pay recurring fees at monthly, quarterly, or annual intervals.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyMonthly subscription at $99/month
SubscriptionPay-as-you-goQuarterly subscription at $249/quarter
SubscriptionAnnualAnnual subscription at $850/year

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Chimera Research Group product offering

Product offering

Core offering

Chimera Research Group delivers a subscription-based equity research service for the biotech and pharmaceutical sectors, providing independent, actionable investment and trading ideas backed by comprehensive fundamental research. Coverage focuses on early-stage companies with impending FDA decisions or clinical trial results and on mid-to-large-cap bio-pharma companies with specific catalysts. Subscribers receive access to Research Reports, Trade Reports, Daily Updates, Charts & Technical Analysis, Real-Time Twitter/email alerts, and a Members-Only Forum that includes contributions from major biotech hedge fund managers and pharmaceutical executives.

Product overview

Chimera Research Group is a subscription-based equity research service for the biotech and pharmaceutical sectors, providing independent investment and trading intelligence. The company offers a unified platform of six integrated service modules: Research Reports covering clinical trials and competitive analysis, Trade Reports with risk-reward optimization, Daily Updates on sector news, Charts & Technical Analysis with entry/exit points, a Members-only Forum with contributions from hedge fund managers and pharma executives, and Real-Time Updates via Twitter and email alerts. Premium features include access to the team's own trade positions and direct analyst communication. The company was founded in 2011 and focuses on early-stage companies with FDA decisions or clinical trial catalysts.

Differentiator

Problem solved

Functional benefit

Products and services

  • Research Reports Peer-reviewed fundamental research reports covering clinical trials, pipelines, and competitive landscapes of biotech and pharmaceutical companies, produced for subscribing investors and industry professionals.
  • Trade Reports Investment and trade analyses providing risk-reward profiles and entry/exit strategies using statistical, scientific, fundamental, and technical analysis, targeted at active biotech stock traders.
  • Daily Update Daily news and development coverage of the biotech and pharmaceutical sectors delivered to subscribers as part of the Chimera Research Group subscription.
  • Charts and Technical Analysis Technical analysis reports with step-by-step chart walkthroughs that mark technical entry and exit points and key support lines for biotech and pharmaceutical stocks.
  • Members-Only Forum Private online community where subscribers interact with Chimera Research Group founders, analysts, and guest contributors, including hedge fund managers from major biotech hedge funds and pharmaceutical executives.
  • Real-Time Updates Service Real-time Twitter feed and email alert service providing instant communication of breaking news and biotech/pharma developments to subscribers.
  • Biotech M&A Deal Database Standalone premium database tools tracking biotech mergers and acquisitions deals across multiple years (2018-2025), accessible to Chimera Research Group subscribers.

Companies that use Chimera Research Group

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Chimera Research Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Chimera Research Group partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Chimera Research Group competitors and assessment

Company assessment

Emerging players

  • InvestorsObserver: Online research and analytics platform providing stock ratings and trade ideas to retail investors — adjacent in delivering actionable trade recommendations at consumer price points.
  • TipRanks: Analyst-rating aggregation and transparency platform serving retail investors; partially overlapping with Chimera's transparency-focused value prop (Team Trades disclosures).

Broad incumbents

  • TheStreet: Financial news and commentary site where David Sobek writes a weekly biotech column — overlap in financial commentary audience and biotech coverage angle.
  • Seeking Alpha: Largest crowdsourced investment research publishing platform where Chimera's own analysts (Jason Chew, David Sobek, Joe Gantoss) contribute — overlapping content and audience, but free/contributor-led rather than subscription-led.
  • Morningstar: Broad investment research and data powerhouse serving institutional and retail investors with analyst reports and ratings — overlapping investment-advice category but much wider mandate.

Direct peers

  • Hedgeye Risk Management: Subscription-based investment research platform with paid tiers, daily notes, and proprietary analyst views — comparable subscription research/business model to Chimera.
  • Argus Research: Independent equity research provider delivering fundamental analysis and reports to institutional and individual investors — a direct comparable in research-as-a-service.
  • Cabot Wealth Network: Subscription investment advisory publisher with sector-focused newsletters and paid tiers — comparable independent retail-investor research subscription model.
  • Zacks Investment Research: Subscription-based equity research firm offering stock analysis, rankings, and premium tiers — directly comparable to Chimera's paid research/reports subscription model.
  • The Motley Fool: Subscription investment research service with tiered memberships and stock recommendations, similar in pricing structure and retail-investor GTM to Chimera.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Chimera Research Group social profiles

Digital presence

Chimera Research Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Chimera Research Group leadership team

Management profile

Number of profiles

Profiles3 records

Chimera Research Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Chimera Research Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chimera Research Group

What does Chimera Research Group do?

Chimera Research Group delivers a subscription-based equity research service for the biotech and pharmaceutical sectors, providing independent, actionable investment and trading ideas backed by comprehensive fundamental research. Coverage focuses on early-stage companies with impending FDA decisions or clinical trial results and on mid-to-large-cap bio-pharma companies with specific catalysts. Subscribers receive access to Research Reports, Trade Reports, Daily Updates, Charts & Technical Analysis, Real-Time Twitter/email alerts, and a Members-Only Forum that includes contributions from major biotech hedge fund managers and pharmaceutical executives.

Is Chimera Research Group a public or private company?

Chimera Research Group is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Chimera Research Group founded?

Chimera Research Group was founded in 2011. It employs 1 to 10 people.

Where is Chimera Research Group based?

Chimera Research Group is headquartered in Genoa, Italy, in the Europe region.

How does Chimera Research Group make money?

One revenue line is on record: subscription Services.

Who are Chimera Research Group's main competitors?

Emerging players on record are InvestorsObserver and TipRanks. Broad incumbents are TheStreet, Seeking Alpha and Morningstar. Direct peers are Hedgeye Risk Management, Argus Research, Cabot Wealth Network, Zacks Investment Research and The Motley Fool.

Does Chimera Research Group have an API?

No public API is recorded for Chimera Research Group.

What industry is Chimera Research Group in?

Chimera Research Group's product category is Biotech Equity Research. Its primary akta.pro industry code is FSACAGAA, Equity Research, with a secondary code of BPAHALAE, Industry & Sector Research (Syndicated/Custom). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales